SCHEMBL23950763

SCHEMBL23950763

Cn1cc(-c2nc(-c3ccc(Cl)cc3)cc3c(=O)n([C@H]4CCCC[C@H]4O)cnc23)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.44
ALOX5 P09917 1/20 0.42
CHRM1 P11229 1/20 0.42
CYP2C9 P11712 1/20 0.42
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
FGFR3 P22607 2/20 0.35
CHEK1 O14757 1/20 0.35
KDR P35968 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
IRAK1 P51617 6/20 0.35
CREBBP Q92793 2/20 0.35
MTOR P42345 1/20 0.34
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23950744 0.89 KCNH2 (0.41) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL23950287 0.89 KCNH2 (0.41) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL23925837 0.89 KCNH2 (0.41) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL23390337 0.88 CNR1 (0.35) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL23390082 0.88 CNR1 (0.35) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL23390520 0.88 CNR1 (0.35) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL23390379 0.88 CNR1 (0.35) KCNH2ALOX5CHRM1CYP2C9JAK2
SCHEMBL25463600 0.87 PIK3CA (0.41) CNR1CNR2FGFR3KDRGSK3B
SCHEMBL23950712 0.87 PIK3CA (0.41) CNR1CNR2FGFR3KDRGSK3B
SCHEMBL25463160 0.85 EGFR (0.38) CNR1CNR2FGFR3IRAK1MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN claimed
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 KCNH2 4013/4885ALOX5 386/4885CHRM1 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.